pranlukasts

Pranlukasts are a class of drugs known as leukotriene receptor antagonists. Their primary mechanism of action involves selectively blocking the binding of leukotrienes to their receptors in the body. Leukotrienes are inflammatory mediators produced by cells such as mast cells and eosinophils. In conditions like asthma and allergic rhinitis, leukotrienes contribute to bronchoconstriction, inflammation, increased mucus production, and edema of the airways. By inhibiting these effects, pranlukasts aim to reduce the symptoms associated with these conditions.

Pranlukasts are typically administered orally. They are prescribed for the management of chronic asthma in patients who are not adequately controlled by other therapies. They may also be used for the symptomatic relief of allergic rhinitis. Clinical studies have demonstrated their efficacy in improving lung function, reducing the frequency of asthma attacks, and alleviating nasal symptoms. However, they are generally not intended for the immediate relief of acute bronchospasm.

While generally well-tolerated, potential side effects of pranlukasts can include gastrointestinal disturbances such as abdominal pain and diarrhea, as well as headache and fatigue. In rare cases, neuropsychiatric effects have been reported. It is important for patients to consult with a healthcare professional to determine if pranlukasts are an appropriate treatment option and to discuss any potential risks and benefits. They are not a substitute for bronchodilator therapy in acute asthma attacks.